12/10/2013 2:00:00 AM
In his presentation, titled “Advances in Biomarkers for Muscle Biology: Muscle Mass (Non-Invasive), Turnover of Muscle Proteome and ‘Virtual Biopsy’ of Muscle Protein Synthesis,” Marc Hellerstein, M.D., Ph.D., KineMed’s President, CSO, and Scientific Founder will discuss important advances in biomarker technology crucial to the development of treatments for muscle wasting diseases. Such diseases include cancer-related cachexia, sarcopenia, and Duchenne’s muscular dystrophy.
11/6/2013 2:00:00 AM
KineMed, Inc. today announced that Dr. Mahalakshmi Shankaran, Director of Muscle and Neurobiology at KineMed, Inc., will present preclinical data demonstrating the use of KineMed’s biomarker platform technology to measure the effects of Plexxikon’s FMS kinase inhibitor, PLX5622, on neuroinflammation at the 43rd annual meeting of the Society for Neuroscience being held in San Diego, California, November 9-13, 2013.
10/15/2013 1:00:00 AM
KineMed, Inc. announces an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.
Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer
talks about the power of Proteome Dynamics at the Personalized Medicine World Conference